Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO).

Mario Caccese,Marta Padovan,Marica Eoli,Alessia Pellerino,Simona Rizzato,Claudia Caserta,Matteo Simonelli,Maria Michiara,Vittorina Zagonel,Roberta Rudà,Giuseppe Lombardi

Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO).

2020

Mario Caccese
Marta Padovan
Marica Eoli
Alessia Pellerino
Simona Rizzato
Claudia Caserta
Matteo Simonelli
Maria Michiara
Vittorina Zagonel
Roberta Rudà
Giuseppe Lombardi

2544Background: Precision medicine is a promising tool in oncology. Depatux-M is a new antibody-drug conjugate, consisting of a specific antibody against activated EGFR and a cytotoxic agent with a...

Keywords:

multicenter study
Oncology
recurrent glioblastoma
Internal medicine
Pathology
Medicine
Temozolomide
neuro oncology
Precision medicine
Depatuxizumab mafodotin
specific antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations